{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00190",
  "@type" : "Drug",
  "administrationRoute" : "oral",
  "availableStrength" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:8ceb47939fa8538e2459110add6d3c07",
    "@type" : "DrugStrength",
    "description" : "25 mg Tablet form with oral route"
  },
  "clinicalPharmacology" : "Carbidopa, a noncompetitive decarboxylase inhibitor, is used in combination with levodopa for the treatment of Parkinson's disease.",
  "cost" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:a31ec87c1c423bde9f1a2b2011e1fe33",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "2.5299999713897705078",
    "drugUnit" : "Lodosyn 25 mg tablet"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:da2ba6bc8076069be5847c656921fd0e",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "27.54000091552734375",
    "drugUnit" : "Carbidopa powder"
  } ],
  "description" : "An inhibitor of DOPA decarboxylase, preventing conversion of levodopa to dopamine. It is used in parkinson disease to reduce peripheral adverse effects of levodopa. It has no antiparkinson actions by itself. [PubChem]",
  "dosageForm" : "Tablet",
  "drugClass" : [ "Dopamine Agents", "Enzyme Inhibitors", "Antiparkinson Agents", "Antidyskinetics" ],
  "identifier" : "drugbank:DB00190",
  "interactingDrug" : "DDI between Carbidopa and Droxidopa - Carbidopa may diminish the therapeutic effect of Droxidopa. Carbidopa may decrease serum concentrations of the active metabolite(s) of Droxidopa. Carbidopa may increase the serum concentration of Droxidopa.",
  "legalStatus" : "Approved",
  "manufacturer" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:30029b2b8f8ea94d9f5461d121d2f162",
    "@type" : "Organization",
    "name" : "Aton pharma inc"
  },
  "mechanismOfAction" : "When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic L-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the CNS. Carbidopa also inhibits the metabolism of levodopa in the GI tract, thus, increasing the bioavailability of levodopa.",
  "name" : "Carbidopa",
  "nonProprietaryName" : [ "Carbidopum monohydricum", "(S)-carbidopa hydrate", "(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate", "L-alpha-(3,4-Dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate", "(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate", "(S)-(?)-carbidopa hydrate", "carbidopa hydrate", "Carbidopa monohydrate", "(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate", "Carbidopum", "(S)-(-)-Carbidopa hydrate", "(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate" ],
  "sameAs" : [ "http://www.drugbank.ca/drugs/DB00190", "http://www.rxlist.com/cgi/generic/sinemet.htm", "http://www.drugs.com/cdi/carbidopa.html" ],
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00190.html"
}